Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06–2018 study)
| Autor: | Amari, Lyria a, Tomasini, Pascale b, Dantony, Emmanuelle c, d, Rousseau-Bussac, Gaelle e, Ricordel, Charles f, Bigay-Game, Laurence g, Arpin, Dominique h, Morel, Hugues i, Veillon, Remi j, Justeau, Grégoire k, Huchot, Eric l, Fournel, Pierre m, Vergnenegre, Alain n, Bizeux, Acya o, Subtil, Fabien c, d, Clarisse, Bénédicte p, Decroisette, Chantal q, Chouaid, Christos e, Greillier, Laurent b, Bylicki, Olivier a, ⁎, 1 |
|---|---|
| Zdroj: | In Lung Cancer July 2024 193 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect